Log In
Print this Print this

MV-CHIK vaccine

  Manage Alerts
Collapse Summary General Information
Company Themis Bioscience GmbH
DescriptionVaccine developed using Thermaxyn technology that uses a single measles virus vector expressing the chikungunya E1 and E2 proteins
Molecular Target
Mechanism of ActionVaccine
Therapeutic ModalityPreventive vaccine: Viral vaccine
Latest Stage of DevelopmentPhase II
Standard IndicationChikungunya virus
Indication DetailsPrevent chikungunya virus infection
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today